Global RNAi Technology Market Growth (Status and Outlook) 2025-2031

According to this study, the global RNAi Technology market size will reach US$ million by 2031.

RNA interference is a relatively new concept in the field of medicine. It is a process in which the ribonucleic acid inhibits translation or gene expression by converting single-stranded mRNA to double stranded RNA, thereby neutralizing the target nucleic acids.

As an important force driving a new round of scientific and technological revolution, artificial intelligence has been of national strategic importance. Many governments introduces polices and increase capital investment to support AI companies. The Digital Europe plan adopted by the European Union will allocate €9.2 billion on high-tech investments, such as supercomputing, artificial intelligence, and network security. In order to maintain its leading position, the United States will increase its investment in artificial intelligence research and development in non-defense fields, from US$1.6 billion to US$1.7 billion in 2022. According to the latest data released by IDC, global artificial intelligence revenue was US$432.8 billion in 2022, a year-on-year increase of 19.97%, including software, hardware and services.

LPI (LP Information)' newest research report, the “RNAi Technology Industry Forecast” looks at past sales and reviews total world RNAi Technology sales in 2024, providing a comprehensive analysis by region and market sector of projected RNAi Technology sales for 2025 through 2031. With RNAi Technology sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world RNAi Technology industry.

This Insight Report provides a comprehensive analysis of the global RNAi Technology landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on RNAi Technology portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global RNAi Technology market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for RNAi Technology and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global RNAi Technology.

This report presents a comprehensive overview, market shares, and growth opportunities of RNAi Technology market by product type, application, key players and key regions and countries.

Segmentation by Type:
Cancer
Liver Disorders
Respiratory Disorders
Neurological Disorders
Autoimmune Disorders
Others

Segmentation by Application:
Drug Discovery & Development
Therapeutics
Drug Delivery
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Alnylam Pharmaceuticals
Dicerna Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc.
Arbutus Biopharma
Benitec Biopharma
Calando
Silence Therapeutics
Gotham Therapeutics

Please note: The report will take approximately 2 business days to prepare and deliver. Show more